

## Structural Elucidation of Scyphostatin, an Inhibitor of Membrane-Bound Neutral Sphingomyelinase

Masahiro Tanaka,<sup>†</sup> Futoshi Nara,<sup>‡</sup> Keiko Suzuki-Konagai,<sup>†</sup> Tsuyoshi Hosoya,<sup>§</sup> and Takeshi Ogita<sup>\*†</sup>

Biomedical Research Laboratories, Sankyo Co., Ltd.  
2-58, Hiromachi 1-chome, Shinagawa-ku Tokyo, 140 Japan  
Biological Research Laboratories, Sankyo Co., Ltd.  
2-58, Hiromachi 1-chome, Shinagawa-ku Tokyo, 140 Japan  
Tsukuba Research Laboratories, Sankyo Co., Ltd.  
33, Miyukigaoka, Tsukuba-shi Ibaraki, 305 Japan

Received April 28, 1997

Revised Manuscript Received June 19, 1997

Signal transduction pathways via the sphingomyelin cycle have attracted much attention since ceramide, a product of sphingomyelinase, was found to play an important role in vitamin D<sub>3</sub>-induced differentiation in HL-60 cells.<sup>1</sup> Ceramide is an intracellular lipid second messenger and takes part in the regulation of cell proliferation, differentiation, and apoptosis in a wide variety of cell types.<sup>2</sup> In particular, sphingomyelin breakdown by membrane-bound neutral sphingomyelinase (N-SMase) appears downstream of signaling events of inflammatory cytokines including TNF $\alpha$  and IL-1 $\beta$ , and this ceramide generation has been reported to mediate prostaglandin production and cytokine gene expression.<sup>3–7</sup> Although these cytokines are believed to play essential roles in many physiological processes including immune responses, uncontrolled production of the cytokines causes severe tissue damage and leads to a variety of pathological states.<sup>8</sup> Thus, inhibition of N-SMase may lead to regulation of ceramide levels and to therapy for inflammation and autoimmune diseases.

With this aim in mind, N-SMase inhibitors were sought for in fermentation broths of microorganisms, and scyphostatin (**1**) (Figure 1)<sup>9</sup> was discovered in a mycelial extract of *Dasyyscyphus mollissimus* SANK-13892. **1** exhibited potent inhibitory activity (IC<sub>50</sub> = 1.0  $\mu$ M) to N-SMase;<sup>10</sup> on the other hand, acidic SMase was inhibited at high concentrations (IC<sub>50</sub> = 49.3  $\mu$ M). To our knowledge, this is the first inhibitor of the enzyme from either natural sources or synthetic origin except for ganglioside GM3 (IC<sub>50</sub> = 45  $\mu$ M).<sup>10</sup> In this report, we describe the structural elucidation of **1**.




Figure 1. Structure of scyphostatin (**1**).

<sup>†</sup> Biomedical Research Laboratories.

<sup>‡</sup> Biological Research Laboratories.

<sup>§</sup> Tsukuba Research Laboratories.

(1) Okazaki, T.; Bell, R. M.; Hannun, Y. A. *J. Biol. Chem.* **1989**, *264*, 19076–19080.

(2) For recent reviews, see: (a) Obeid, L. M.; Hannun, Y. A. *J. Cell. Biochem.* **1995**, *58*, 191–198. (b) Hannun, Y. A. *Science* **1996**, *274*, 1855–1859. (c) Spiegel, S.; Merrill, A. H. *FASEB J.* **1996**, *10*, 1388–1397. (d) Kolesnick, R.; Golde, D. W. *Cell* **1994**, *77*, 325–328. (e) Ballou, L. R.; Lauderkind, S. J. F.; Rosloniec, E. F.; Raghov, R. *Biochim. Biophys. Acta* **1996**, *1301*, 273–287.

(3) Candela, M.; Barker, S. C.; Ballou, L. R. *J. Exp. Med.* **1991**, *174*, 1363–1369.

(4) Ballou, L. R.; Chao, C. P.; Holness, M. A.; Barker, S. C.; Raghov, R. *J. Biol. Chem.* **1992**, *267*, 20044–20050.

(5) Mathias, S.; Younes, A.; Kan, C. C.; Orlov, I.; Joseph, C.; Kolesnick, R. N. *Science* **1993**, *259*, 519–522.

Table 1. NMR Data of Scyphostatin (**1**) (360 MHz, in CD<sub>3</sub>OD)

pos	$\delta_C$	$\delta_H$	pos	$\delta_C$	$\delta_H$
1	65.6	3.45 (1H, dd, $J = 10.9, 5.8$ Hz)	7'	146.4	5.70 (1H, dd, $J = 15.1, 8.7$ Hz)
		3.52 (1H, dd, $J = 10.9, 5.1$ Hz)	8'	36.7	2.35 (1H, m)
2	48.5	4.05 (1H, m)	9'	45.7	1.10 (1H, m)
3	40.3	1.89 (1H, m)			1.33 (1H, m)
		2.08 (1H, dd, $J = 14.7, 3.6$ Hz)	10'	30.0	1.59 (1H, m)
4	78.0		11'	50.1	1.79 (1H, m)
5	58.7	3.67 (1H, d, $J = 3.9$ Hz)			1.89 (1H, m)
6	49.8	3.59 (1H, m)	12'	134.0	
7	146.6	7.15 (1H, m)	13'	134.7	4.84 (1H, m) <sup>a</sup>
8	132.5	6.07 (1H, dd, $J = 9.8, 1.6$ Hz)	14'	35.9	2.27 (1H, m)
9	201.0		15'	32.6	1.19 (1H, m)
1'	169.0				1.33 (1H, m)
2'	124.3	5.89 (1H, d, $J = 14.8$ Hz)	16'	13.0	0.86 (3H, t, $J = 7.4$ Hz)
3'	142.9	7.15 (1H, m)	17'	22.0	0.91 (3H, d, $J = 6.9$ Hz)
4'	129.9	6.25 (1H, dd, $J = 14.9, 11.1$ Hz)	18'	16.9	1.54 (3H, d, $J = 1.3$ Hz)
5'	141.9	6.53 (1H, dd, $J = 14.9, 10.7$ Hz)	19'	20.4	0.83 (3H, d, $J = 6.5$ Hz)
6'	130.4	6.15 (1H, dd, $J = 15.1, 10.7$ Hz)	20'	22.4	1.00 (3H, d, $J = 6.7$ Hz)

<sup>a</sup> Signal was detected with a WEFT experiment.




Figure 2. Partial structures of **1**.

Scyphostatin (**1**) [UV  $\lambda_{\max}$ (MeOH) ( $\epsilon$ ) 300 nm (41 500),  $[\alpha]_D^{25} +66.4^\circ$  ( $c$  0.09 in MeOH)] was isolated as a colorless oil and the molecular formula was determined to be C<sub>29</sub>H<sub>43</sub>NO<sub>5</sub> ([M + H]<sup>+</sup>,  $m/z$  486.3199  $\Delta$  -0.5 mmu) on the basis of high-resolution FABMS spectral analyses. The structural study was mainly carried out by interpretation of NMR spectra taken in CD<sub>3</sub>OD. <sup>1</sup>H and <sup>13</sup>C NMR spectral data are summarized in Table 1. The DQFCOSY spectrum revealed two spin systems, C-2' through C-11' and C-13' through C-16', which were in turn connected by the C-12' olefinic quaternary carbon based on long-range correlations of 18'-H with C-11', C-12', and C-13' in HMBC experiments. The geometry of the conjugated triene was determined to be all *E* based on the large coupling constants ( $J_{2'-3'} = 14.8$  Hz,  $J_{4'-5'} = 14.9$  Hz, and  $J_{6'-7'} = 15.1$  Hz) of the corresponding olefinic proton signals, and the C-12' double bond was determined to be *E* because of the chemical shift of the C-18' methyl resonance at higher field (16.9 ppm). Long-range correlations of C-1' with 2'-H and 3'-H were observed revealing that **1** has a conjugated acyl group (partial structure I) as depicted

(6) Dbaibo, G. S.; Obeid, L. M.; Hannun, Y. A. *J. Biol. Chem.* **1993**, *268*, 17762–17766.

(7) Lauderkind, S. J. F.; Bielawska, A.; Raghov, R.; Hannun, Y. A.; Ballou, L. R. *J. Exp. Med.* **1995**, *182*, 599–605.

(8) For reviews, see: (a) Dinarello, C. A. *Blood* **1991**, *77*, 1627–1652. (b) Arend, W. P.; Dayer, J. M. *Arthritis-Rheum.* **1995**, *38*, 151–160.

(9) The isolation, fermentation, and biological activities of scyphostatin will be reported soon elsewhere.

(10) The inhibitory activity of scyphostatin was determined using rat brain microsome fraction as an enzyme source. The extent of N-SMase reaction was evaluated by measuring of the [<sup>14</sup>C]choline phosphate production from [<sup>14</sup>C]sphingomyelin under a neutral condition as previously described, see: Lister, M. D.; Crawford-Redick, C. L.; Loomis, C. R. *Biochim. Biophys. Acta* **1993**, *1165*, 314–320.

